UroGen Pharma Operating Expenses Growth & History (URGN)
UroGen Pharma's operating expenses was $222.2M for fiscal 2025.
View full UroGen Pharma company overviewUroGen Pharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $222.2M | $43.9M | +24.62% |
| 2024 | 2024-12-31 | $178.3M | $39.4M | +28.38% |
| 2023 | 2023-12-31 | $138.9M | $3.1M | +2.32% |
| 2022 | 2022-12-31 | $135.7M | $567,000 | +0.42% |
| 2021 | 2021-12-31 | $135.2M | −$2.4M | −1.71% |
| 2020 | 2020-12-31 | $137.5M | $28.0M | +25.60% |
| 2019 | 2019-12-31 | $109.5M | $33.0M | +43.12% |
| 2018 | 2018-12-31 | $76.5M | $49.0M | +178.12% |
| 2017 | 2017-12-31 | $27.5M | $10.8M | +64.68% |
| 2016 | 2016-12-31 | $16.7M | — | — |
UroGen Pharma quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $65.8M | $3.7M | +5.89% |
| Q1 2026 | 2026-03-31 | $67.1M | $12.2M | +22.33% |
| Q4 2025 | 2025-12-31 | $53.7M | $3.9M | +7.86% |
| Q3 2025 | 2025-09-30 | $51.6M | $11.3M | +28.03% |
| Q2 2025 | 2025-06-30 | $62.1M | $16.7M | +36.64% |
| Q1 2025 | 2025-03-31 | $54.8M | $12.0M | +28.15% |
| Q4 2024 | 2024-12-31 | $49.8M | $13.9M | +38.77% |
| Q3 2024 | 2024-09-30 | $40.3M | $8.3M | +25.98% |
| Q2 2024 | 2024-06-30 | $45.5M | $11.4M | +33.39% |
| Q1 2024 | 2024-03-31 | $42.8M | $5.8M | +15.74% |
| Q4 2023 | 2023-12-31 | $35.9M | −$258,000 | −0.71% |
| Q3 2023 | 2023-09-30 | $32.0M | −$179,000 | −0.56% |
| Q2 2023 | 2023-06-30 | $34.1M | $605,000 | +1.81% |
| Q1 2023 | 2023-03-31 | $37.0M | $3.0M | +8.75% |
| Q4 2022 | 2022-12-31 | $36.1M | $1.6M | +4.67% |
| Q3 2022 | 2022-09-30 | $32.2M | −$1.4M | −4.12% |
| Q2 2022 | 2022-06-30 | $33.5M | −$955,000 | −2.77% |
| Q1 2022 | 2022-03-31 | $34.0M | $1.3M | +3.96% |
| Q4 2021 | 2021-12-31 | $34.5M | — | — |
| Q3 2021 | 2021-09-30 | $33.5M | $1.3M | +3.94% |
| Q2 2021 | 2021-06-30 | $34.4M | $2.3M | +7.17% |
| Q1 2021 | 2021-03-31 | $32.7M | — | — |
| Q3 2020 | 2020-09-30 | $32.3M | $8.8M | +37.62% |
| Q2 2020 | 2020-06-30 | $32.1M | $8.4M | +35.14% |
| Q4 2019 | 2019-12-31 | $39.8M | $15.8M | +65.88% |
| Q3 2019 | 2019-09-30 | $23.5M | $3.1M | +15.44% |
| Q2 2019 | 2019-06-30 | $23.8M | $5.3M | +28.63% |
| Q1 2019 | 2019-03-31 | $22.4M | $8.7M | +63.85% |
| Q4 2018 | 2018-12-31 | $24.0M | $13.8M | +135.51% |
| Q3 2018 | 2018-09-30 | $20.3M | $12.5M | +159.81% |
| Q2 2018 | 2018-06-30 | $18.5M | $12.5M | +210.54% |
| Q1 2018 | 2018-03-31 | $13.7M | $10.2M | +286.86% |
| Q4 2017 | 2017-12-31 | $10.2M | — | — |
| Q3 2017 | 2017-09-30 | $7.8M | — | — |
| Q2 2017 | 2017-06-30 | $6.0M | — | — |
| Q1 2017 | 2017-03-31 | $3.5M | — | — |
UroGen Pharma operating expenses trends
Over the last five fiscal years, UroGen Pharma's operating expenses increased from $137.5M to $222.2M, a change of $84.7M. The latest reported quarter, Q2 2026, shows $65.8M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review UroGen Pharma source filings ↗